NASDAQ:PACB - Pacific Biosciences of California Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $7.23 -0.11 (-1.50 %) (As of 05/19/2019 04:00 PM ET)Previous Close$7.23Today's Range$7.19 - $7.3652-Week Range$2.43 - $7.84Volume1.46 million shsAverage Volume1.48 million shsMarket Capitalization$1.10 billionP/E RatioN/ADividend YieldN/ABeta2.34 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, Africa, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California. Receive PACB News and Ratings via Email Sign-up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services SectorMedical Current SymbolNASDAQ:PACB Previous Symbol CUSIP69404D10 CIK1299130 Webwww.pacb.com Phone650-521-8000Debt Debt-to-Equity Ratio0.47 Current Ratio2.50 Quick Ratio2.06Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$78.63 million Price / Sales14.04 Cash FlowN/A Price / Cash FlowN/A Book Value$0.62 per share Price / Book11.66Profitability EPS (Most Recent Fiscal Year)($0.76) Net Income$-102,560,000.00 Net Margins-143.62% Return on Equity-102.01% Return on Assets-64.34%Miscellaneous Employees401 Outstanding Shares152,680,000Market Cap$1.10 billion Next Earnings Date8/1/2019 (Estimated) OptionableOptionable Pacific Biosciences of California (NASDAQ:PACB) Frequently Asked Questions What is Pacific Biosciences of California's stock symbol? Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB." How were Pacific Biosciences of California's earnings last quarter? Pacific Biosciences of California (NASDAQ:PACB) announced its quarterly earnings results on Friday, May, 3rd. The biotechnology company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.03. The biotechnology company had revenue of $16.43 million for the quarter, compared to analyst estimates of $21.83 million. Pacific Biosciences of California had a negative return on equity of 102.01% and a negative net margin of 143.62%. View Pacific Biosciences of California's Earnings History. When is Pacific Biosciences of California's next earnings date? Pacific Biosciences of California is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for Pacific Biosciences of California. What price target have analysts set for PACB? 4 analysts have issued 1 year price objectives for Pacific Biosciences of California's stock. Their predictions range from $3.80 to $8.00. On average, they expect Pacific Biosciences of California's share price to reach $6.5750 in the next year. This suggests that the stock has a possible downside of 9.1%. View Analyst Price Targets for Pacific Biosciences of California. What is the consensus analysts' recommendation for Pacific Biosciences of California? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pacific Biosciences of California. What are Wall Street analysts saying about Pacific Biosciences of California stock? Here are some recent quotes from research analysts about Pacific Biosciences of California stock: 1. Cantor Fitzgerald analysts commented, "We think PACB’s long-read next-generation sequencing platform is the industry standard for deep genomic analysis in human, plant, and animal genomes, as well as RNA. The company has seen mixed revenue performance over the past three years, but we think PACB is getting close to an inflection point, which we think the Street is missing. We see the path to revenue acceleration as multifactorial. These include the launch of its 8 million ZMW SMRT cell, increased penetration of the plant and animal sequencing market, and significant sequencing cost reduction per human genome enabling PACB to become a more mainstream player in human genomics." (5/3/2019) 2. According to Zacks Investment Research, "Pacific Biosciences has been gaining grounds in the MedTech space, thanks to strong Sequel performance, which witnessed record bookings. Meanwhile, one of Pacific Biosciences’ biggest rival — Illumina — recently announced that it is acquiring the former for $8 per Pacific Biosciences share (in an all-cash transaction). Per management, the total value of the deal is approximately $1.2 billion. The agreement is expected to close by mid-2019. Reflective of these, the company outperformed its industry in a year’s time. On the flip side, dull performance in the service and other revenue segment stemming from lower instrument revenues is a headwind. The DNA sequencing market is rife with competition. Sales in Europe declined considerably in the last-reported quarter. Also, higher operating expenses are likely to mar prospects." (4/16/2019) Has Pacific Biosciences of California been receiving favorable news coverage? Press coverage about PACB stock has trended somewhat positive this week, according to InfoTrie. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Pacific Biosciences of California earned a coverage optimism score of 1.9 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. Are investors shorting Pacific Biosciences of California? Pacific Biosciences of California saw a increase in short interest during the month of April. As of April 15th, there was short interest totalling 22,123,638 shares, an increase of 6.0% from the March 29th total of 20,862,424 shares. Based on an average daily trading volume, of 1,315,027 shares, the days-to-cover ratio is currently 16.8 days. Currently, 16.2% of the shares of the company are short sold. View Pacific Biosciences of California's Current Options Chain. Who are some of Pacific Biosciences of California's key competitors? Some companies that are related to Pacific Biosciences of California include Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Fluidigm (FLDM), Quanterix (QTRX), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), Arrayit (ARYC), Precipio (PRPO), BioNano Genomics (BNGO), Aethlon Medical (AEMD), Scientific Industries (SCND), Pressure Biosciences (PBIO) and PositiveID (PSID). What other stocks do shareholders of Pacific Biosciences of California own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Illumina (ILMN), Novavax (NVAX), CenterPoint Energy (CNP), Alkaline Water (WTER), bluebird bio (BLUE), FireEye (FEYE), Incyte (Incy), Juno Therapeutics (JUNO), Alibaba Group (BABA) and EXACT Sciences (EXAS). Who are Pacific Biosciences of California's key executives? Pacific Biosciences of California's management team includes the folowing people: Dr. Michael W. Hunkapiller, Exec. Chairman, CEO & Pres (Age 70)Ms. Susan K. Barnes, Exec. VP & CFO (Age 65)Mr. James Michael Phillips, Sr. VP of R&D (Age 68)Dr. Stephen Turner, Co-Founder & CTO (Age 51)Dr. Jonas Korlach Ph.D., Chief Scientific Officer Who are Pacific Biosciences of California's major shareholders? Pacific Biosciences of California's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.30%), CNH Partners LLC (4.42%), Alpine Associates Management Inc. (3.98%), Water Island Capital LLC (2.40%), Water Island Capital LLC (2.37%) and ArrowMark Colorado Holdings LLC (2.22%). Company insiders that own Pacific Biosciences of California stock include James Michael Phillips, Kathy Ordonez, Michael Hunkapiller and Susan K Barnes. View Institutional Ownership Trends for Pacific Biosciences of California. Which institutional investors are selling Pacific Biosciences of California stock? PACB stock was sold by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Stevens Capital Management LP, Arrowgrass Capital Partners US LP, BlackRock Inc., Morgan Stanley, ArrowMark Colorado Holdings LLC, Frontier Capital Management Co. LLC and Moloney Securities Asset Management LLC. Company insiders that have sold Pacific Biosciences of California company stock in the last year include James Michael Phillips, Kathy Ordonez, Michael Hunkapiller and Susan K Barnes. View Insider Buying and Selling for Pacific Biosciences of California. Which institutional investors are buying Pacific Biosciences of California stock? PACB stock was bought by a variety of institutional investors in the last quarter, including Water Island Capital LLC, Water Island Capital LLC, ARP Americas LP, Alpine Associates Management Inc., Caisse DE Depot ET Placement DU Quebec, Gabelli Funds LLC, GABELLI & Co INVESTMENT ADVISERS INC. and Man Group plc. View Insider Buying and Selling for Pacific Biosciences of California. How do I buy shares of Pacific Biosciences of California? Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Pacific Biosciences of California's stock price today? One share of PACB stock can currently be purchased for approximately $7.23. How big of a company is Pacific Biosciences of California? Pacific Biosciences of California has a market capitalization of $1.10 billion and generates $78.63 million in revenue each year. The biotechnology company earns $-102,560,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. Pacific Biosciences of California employs 401 workers across the globe. What is Pacific Biosciences of California's official website? The official website for Pacific Biosciences of California is http://www.pacb.com. How can I contact Pacific Biosciences of California? Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected] MarketBeat Community Rating for Pacific Biosciences of California (NASDAQ PACB)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 290 (Vote Outperform)Underperform Votes: 262 (Vote Underperform)Total Votes: 552MarketBeat's community ratings are surveys of what our community members think about Pacific Biosciences of California and other stocks. Vote "Outperform" if you believe PACB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PACB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: Understanding Analyst Recommendations Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.